Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

What Is Psychedelic-Assisted Therapy?

What psychedelic therapy means in research and licensed settings, using natural psilocybin as the main example: the parts of a treatment course, what two trials found, and why it is not the same as a retreat.

Content last updated . This page has not been medically reviewed.

Back to Psychedelic Therapy
Quick answer
"Psychedelic therapy" (also called psychedelic-assisted therapy) describes a treatment course in which a natural psychedelic is given inside a structured program of psychological support. It is not the substance alone. Most of the modern research is on psilocybin, the active compound in certain mushrooms and truffles. Plant traditions such as ayahuasca, iboga, and peyote or San Pedro cactus are part of the wider story, but the sources used here are about psilocybin.

The parts of a treatment course

In a treatment course, the psychedelic is usually paired with preparation before, support during, and follow-up after. In Oregon's licensed program, for example, "psilocybin services" means preparation, administration and integration sessions provided by a licensed facilitator. [2]

The FDA says some development programs include a psychological or behavioral intervention, and that the contribution of the psychotherapy part to any benefit has not been characterized. [1] In plain terms: nobody yet knows how much of a trial result comes from the substance, how much from the therapy, and how much from the combination.

The therapy itself is not one standard method. A systematic review found ad hoc and adapted methods, with differences in therapeutic stance, how directive the therapist is, and how much information is given to patients. [3]

What psilocybin research looks like

  • Psilocybin for major depression (27 adults, waitlist comparison). Two psilocybin sessions were given with about 11 hours of supportive psychotherapy. [4] Depression scores were lower in the immediate-treatment group than in the group still waiting. [4] This was small, with a waitlist comparison rather than a placebo. Label: promising but limited.
  • Psilocybin for treatment-resistant depression (phase 2, 233 adults). The higher study dose, but not the lower one, beat a very low comparison dose at 3 weeks. Adverse events occurred in 77% of participants, and suicidal thoughts or self-injury occurred in all dose groups. [5] Label: mixed.

A strong effect can let people guess what they received, which is a known problem for reading results. See how to read a psychedelic clinical trial and research limits.

A 2020 review concluded the evidence was not then enough for FDA approval of any psychedelic for routine psychiatric use. [6] Regulatory status changes, and this page does not state current approval status. Psychedelic therapy remains investigational. Read what is and is not approved.

Not the same as retreats

The safeguards described on this page come from research protocols and regulators: screening, trained monitors, medical backup. This page does not assess retreats or other unregulated settings, including those built around plant traditions, and nothing here shows that they provide those safeguards. See evaluating retreat claims.

Related guides

Frequently asked questions

Is psychedelic therapy the same as taking a psychedelic?

No. In the trials and licensed programs described here, the substance is one part of a course that includes preparation, monitored sessions and follow-up. [2] The substance alone is not what was tested.

Does the therapy part matter?

Nobody knows yet. The FDA states that the contribution of the psychotherapy component has not been characterized. [1]

Is it approved?

This page does not give current approval status, because we did not read a regulator page for it. Psychedelic therapy is investigational. See the page on medical approval.

Is it safe?

Trials report adverse events, including serious distress in some people. In one psilocybin trial, 77% of participants had an adverse event. [5] Safety in a monitored trial does not carry over to unsupervised settings.

Where can I talk about this for my own situation?

With your own doctor or mental health professional. If you are in crisis in the US, call or text 988.

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

How to read the evidence labels

Labels used on this page: promising but limited (some controlled trials, small or short), mixed (results differ by study or outcome), insufficient evidence (too little to judge).

Safety first
This page is information only. It does not tell anyone to use any substance, and it gives no amounts or instructions. If you are in crisis in the US, call or text 988, or call 911 in an emergency.
Licensed services are not the same as clinical treatment
Oregon's program requires no prescription or referral and is limited to adults 21 or older. [2] Psilocybin remains a Schedule I substance under federal law (Oregon Health Authority, read 2026-10-22). [7] A reviewer has also cautioned that psychedelics remain investigational and are not yet appropriate for general clinical use. [8] State-regulated services, trials and approved medicines are three different things. Laws change and this is not legal advice; see legal status by country.
References
  1. U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
  2. Oregon Health Authority. Access Psilocybin Services. Read 2026-10-22.
  3. Psychedelic-Assisted Psychotherapy: A Systematic Review of Associated Psychological Interventions. Frontiers in Psychology, 2022. Read 2026-10-22.
  4. Davis AK et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2021. Read 2026-10-22.
  5. Goodwin GM et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 2022. Read 2026-10-22.
  6. Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 2020. Read 2026-10-22.
  7. Oregon Health Authority. What Are Psilocybin Services?. Read 2026-10-22.
  8. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services, 2023. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.